















MichaReduced-Intensity Conditioning before Allogeneic
Hematopoietic Stem Cell Transplantation in Patients
Over 60 Years: A Report from the SFGM-TC
Patrice Chevallier,1 Richard M. Szydlo,2 Didier Blaise,3 Reza Tabrizi,4 Mauricette Michallet,5
Madalina Uzunov,6 Nathalie Fegueux,7 Franc¸ois Guilhot,8 Simona Lapusan,9
Nicole Gratecos,10 Jean-Yves Cahn,11 Gerard Socie,12 Ibrahim Yakoub-Agha,13
Anne Huynh,14 Sylvie Francois,15 Jacques-Olivier Bay,16 Sebastien Maury,17 Agnes Buzyn,18
Nathalie Contentin,19 Mohamad Mohty1This retrospective multicenter report assessed the outcome of 600 patients with hematologic diseases older
than 60 years who received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT), with the specific aim to compare outcomes of patients between 60 and 65 years old
(N 5 493) with those older than 65 years (N 5 107). Except for donor age, there were no significant dif-
ferences between the groups regarding patients, diseases, and allo-HSCT characteristics. At time of RIC
allo-HSCT, 276 patients (46%) were in complete remission.With a median follow-up of 22.8 and 23.7 months
in the younger and the older groups, respectively, 2-year relapse, nonrelapse mortality, disease-free survival,
and overall survival rates were similar in both groups (29.6% vs. 20.4%; 29.9% vs. 34.6%; 40.6% vs. 46.7%;
49.2% vs. 50.2%, respectively; P 5 NS for all comparisons). In a Cox multivariate analysis, after adjustment
for disease and transplant factors, age per se was not an adverse factor for survival (relative risk5 1.08; 95%
confidence interval, 0.81-1.44, P 5 .62). We conclude that in selected patients, RIC allo-HSCT could be
offered to patients over 65 years old.
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The use of the so-called reduced-intensity condi-
tioning (RIC) regimens before allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) has widely
expanded over the last decade, allowing patients with
hematologic diseases and comorbidities or older
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a compromise between maximum myeloablation and
immunosuppression required for successful engraft-
ment. Initial seminal reports of RIC allo-HSCT
demonstrated successful engraftment with a marked
reduction in nonrelapse mortality (NRM), contribut-
ing to the continued increase in allo-HSCT activity
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blative conditioning regimens, RIC regimens have
allowed for decreasing the incidence of overall
NRM. Thus, several retrospective comparisons of
outcomes between myeloablative and RIC regimens
have shown similar overall survival (OS) rates of effi-
cacy with RIC allo-HSCT [2-7].
At present, assessment of eligibility forRICor stan-
dard myeloablative conditioning based on age and co-
morbidities [8,9] remains a challenging issue in many
patients and different disease settings. Age above 50
years is usually considered a contraindication to the
use of standard myeloablative conditioning, whereas
RIC regimens are offered up to the age of 65 in many
centers (especially in Europe) [3,10-21]. Of note, very
few large studies have reported the outcome of
patients above age 65 who received RIC allo-HSCT
[19,20].
This multicenter report assessed the outcome of
600 patients with hematologic diseases older than
age 60 who received RIC allo-HSCT, with the specific
aim to compare outcomes of patients between 60 and
65 years old to patients older than 65.PATIENTS AND METHODS
Study Design
This was a retrospective multicenter study assess-
ing the results of all consecutive RIC allo-HSCTs
for patients $60 years old with various hematologic
diseases, and reported to the Societe Franc¸aise de
Greffe de Moelle-Therapie Cellulaire (SFGM-TC)
registry between 1998 and 2008. Twenty-six trans-
plant centers participated in the study, with a median
of 13 (range: 6-64) patients per center. The study
was approved by the scientific committee of the
SFGM-TC and performed according to the SFGM-
TC guidelines and to the declaration of Helsinki.Patients and Characteristics
Patients’ disease and transplant characteristics are
summarized in Table 1. The median time between di-
agnosis and allo-HSCTwas 17 (range: 2-485) months.
The median age for the entire cohort was 62.2 (range:
60.0-70.7) years. Diagnoses were as follows: acute leu-
kemia (n5 211; 35%),myelodysplastic/myelopolifera-
tive syndromes (n 5 151; 25%), plasma cell disorders
(n5 88; 15%), lymphomas (n5 78, 13%), chronic leu-
kemias (n5 67; 11%), and aplastic anemia (n5 5, 1%).
The majority of patients were transplanted after 2005
(n5 366, 61%). Overall, 276 patients were in complete
remission (CR) at time of RIC allo-HSCT, and 453 pa-
tients (75%) had high-risk (relapse/refractory or active
disease or status beyond CR1 at transplantation) dis-
ease features, whereas 147 (25%) had a standard-riskdisease. Regarding donor type, 368 patients (61%) re-
ceived allo-HSCT from an HLA-matched related do-
nor, whereas 191 patients (32%) received the graft
from an HLA-matched unrelated donor, and 38 (7%)
from a mismatched donor. HLA characteristics of the
donor were missing in 3 cases. Granulocyte-colony
stimulating factor–mobilized peripheral blood stem
cells were used in 82% of cases (n5 492). The combi-
nation of fludarabine and busulfan was the most com-
monly used RIC regimen (n 5 273, 46%). In the
majority of cases, graft versus-host-disease (GVHD)
prophylaxis consisted of cyclosporine-A alone (n 5
182, 30%) or cyclosporine and mycophenolate mofetil
(n 5 253, 42%). Supportive care was performed ac-
cording to each center’s guidelines and was expected
to be the same in both age groups.
Statistical Methods
The baseline characteristics of the 2 patient groups
were compared using a chi-square test for categoric
data and the Mann-Whitney U test for continuous
data. Probabilities of OS and disease-free survival
(DFS) were calculated using the Kaplan-Meier
method. The probability of NRM and relapse inci-
dence were calculated using the cumulative incidence
procedure, in a competing risks setting, with death in
remission treated as a competing event to relapse.
Dates of onset of acute and chronic GVHD (aGVHD,
cGVHD)werenot available, and therefore proportions
of GVHD were compared between the groups using
the chi-square test for trend. The prognostic impact
of patient, disease, and transplant variables on survival
for the entire study group was examined using the
log-rank test. The variables included in the univariate
analysis were: disease type (lymphoid vs myeloid vs
others), disease risk (standard vs high risk), patient age
at transplantation, patient’s sex, patient and donor cyto-
megalovirus (CMV) status, interval between diagnosis
of disease and transplantation (\12 months, between
12 and 24 months, or 24-48 months, and beyond 48
months), year of transplantation, donor type, source of
stem cells, conditioning regimen (fludarabine/busulfan
vs fludarabine/melphalan vs fludarabine/total body irri-
dation vs others, and fludarabine/total body irridiation
vs others), and GVHD prophylaxis (ciclosporin alone
vs ciclosporin/mycophenolate mofetyl vs ciclosporin/
methotrexate vs others). Variables found to be signifi-
cant at the P\ .20 level were then entered into a multi-
variate proportional hazards analysis together with
patient age group. Data were analyzed using the SPSS
(SPSS, Inc., Chicago, IL) software package.RESULTS
To assess the applicability of RIC allo-HSCT to
the older age group, we compared the characteristics





N 5 107 P
Follow-up: months (range) 22.8 (2-125) 23.7 (2-99) .60
Median age: years (range) 61.7 (60-65) 66.3 (66-71)
Sex: male 322 (65%) 74 (84%) .45
Median time diagnostic-graft: months (range) 17 (2-485) 12 (2-224) .93
Disease type * †
Lymphoid 199 (40%) 33 (30%)
Myeloid 290(58%) 73 (68%)
Aplastic anemia 4 (2%) 1 (2%) .15
Duration of disease pretransplantation
<12 months 195 (39%) 43 (40%)
12-24 months 93 (19%) 18 (17%)
24-48 months 87 (18%) 19 (18%)
>48 months 118 (24%) 27 (25%) .97
Disease risk
Standard 118 (24%) 29 (37%)
High 375 (76%) 78 (63%) .49
Donor type
Sex: male/female/unknown 282/199/12 64/39/4 .45
Median age: years (range) 53.3 (0-78.7) 58.7 (0-80.4) .0002
HLA-matched related donor 297 (60%) 71 (66%)
HLA-matched unrelated donor 159 (32%) 32 (30%)
HLA mismatched donor 35 (7%) 3 (3%)
HLA-unknown 2 (1%) 1 (1%) .29
Patients CMV status
Positive 297 (60%) 62 (58%)
Negative 182 (37%) 44 (41%)
Missing 14 (3%) 1 (1%) .5
Donor CMV status
Positive 227 (46%) 50 (47%)
Negative 251 (51%) 53 (50%)
Missing 15 (3%) 4 (3%) .85
Patient/donor CMV status
Positive/positive 161 (33%) 34 (32%)
Other 310 (63%) 68 (64%)
Missing 22 (4%) 5 (4%) .87
Years of transplantation
1998-2003 108 (22%) 19 (18%)
2004-2005 90 (18%) 17 (16%)
2006 68 (14%) 16 (15%)
2007 104 (21%) 22 (20%)
2008 123 (25%) 33 (31%) .69
Stem cell source
PBSC 396 (80%) 96 (90%)
Bone marrow 58 (12%) 8 (7%)
Cord blood 39 (8%) 3 (3%) .06
Median CD34+ cells infused: 106/kg (range) 5.5 (0.02-31.1) 5.1 (1.2-14.3) .45
GVHD prophylaxis
CsA and MMF 214 (43%) 39 (36%)
CsA and methotrexate 80 (16%) 17 (16%)
CsA alone 146 (30%) 36 (34%)
Other 53 (11%) 15 (14%) .51
Type of RIC
Fludarabine/busulfan 225 (46%) 48 (45%)
Fludarabine/TBI low dose 114 (23%) 30 (28%)
Fludarabine/melphalan 20 (4%) 2 (2%)
Others 134 (27%) 27 (25%) .54
ATG: yes/no/unknown 258/179/56 57/41/9 .67
CMV indicates cytomegalovirus; PBSC, peripheral blood stem cells; GVHD, graft-versus-host disease; CsA, cyclosporine A; MMF, mycophenolate
mofetyl; RIC, reduced-intensity conditioning; TBI, total body irradiation; ATG, antithymoglobulin.
*Type of disease, patients 60-65 years: acute myeloid leukemia: n 5 157; acute lymphoblastic leukemia: n 5 15; lymphoma: n 5 66; myeloma: n 5 79,
myelodysplastic or myeloproliferative syndrome: n 5 116; chronic myeloid leukemia: n 5 17; other chronic leukemia: n 5 5; chronic lymphocytic
leukemia: n 5 34.
†Type of disease patients >65 years: acute myeloid leukemia: n5 38; acute lymphoblastic leukemia: n5 1; lymphoma: n5 12; myeloma: n5 9, myelodys-
plastic or myeloproliferative syndrome: n 5 35; chronic lymphocytic leukemia: n 5 11.
Biol Blood Marrow Transplant 18:289-294, 2012 291RIC Allo-HSCT in Elderly Patientsof patients age 60 to 65 (n5 493; median561.7 years)
and those .65 years old (n 5 107; median 5 66.3
years). Patient, disease, and transplant characteristicsand outcomes are summarized in Tables 1A and B. Ex-
cept for donor age, in univariate analysis, these 2 groups
were not statistically different in terms of demographic,




N 5 107 P
Days to neutrophil engraftment (median, range) 17 days(1-60) 18 days(8-28) .50
Acute graft-versus-host disease (GVHD)
Grade 0-1 250 (50%) 45 (42%)
Grade 2 142 (29%) 33 (31%)
Grade 3-4 56 (11%) 14 (13%)
Unknown 45 (10%) 15 (14%) .47
Chronic GVHD (limited/extensive) 109 (22%) (55/54) 25 (23%) (13/12) .93
2-year nonrelapse mortality 29.9% (25.8-34.5) 34.6% (26.2-45.7) .45
2-year relapse rate 29.6% (25.5-34.2) 20.4% (13.9-29.9) .12
Deaths 264 (54%) 56 (52%)
Cause of deaths:
Relapse 111 (42%) 21 (40%)
Graft related 142 (54%) 34 (60%)
Unknown 11 (2%) 1 .44
Alive patients 229 (46%) 51 (48%)
Status of alive patients:




Unknown 38 7 .50
2-year overall survival 49.2% (44.3-54.1) 50.2% (40.6-59.8) .99
2-year disease-free survival 40.6% (36.0-44.4) 46.7% (37.2-56.4) .59
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II-IV and grade III-IV aGVHD occurred in 41% (n5
245) and 12% (n 5 70) of patients, respectively.
Chronic GVHD was observed in 134 patients (22%;
limited: n5 68; 11%; extensive: n5 66, 11%). Overall
2-year NRM reached 28.7% (95% confidence interval
[CI]: 25.1-32.8) (Figure 1A). With a median follow-up
of 22.8 (range: 0.1-125) months for alive patients, the
median OS after allo-HSCT was 23.4 (95% CI: 17.5-
29.3) months. The probability of 2-year OS was
49.4% (95%CI: 45.1-53.7%) (Figure 1A). Disease risk
(2-year OS: standard 49.3% vs high risk 28.1%, P 5
.001) and patient CMV status (2-year OS: positive
35.7% vs negative 59.3%, P 5 .015) were the 2 vari-
ables found to be significant for OS in the univariate
analysis. Patients with myeloid, lymphoid, or other he-
matologic diseases shared similar 2-year OS (31.7 vs
33.8% vs 23.3%, P 5 .92). Also, no center effect was
observed in this series (P 5 .29).Table 1C. Multivariate Analysis for Survival
N RR (95% CI) P
Patient’s age at transplantation (years)
60-65 493 1.00
>65 107 1.08 (0.81-1.44) .62
Disease status at transplantation
Standard risk 147 1.00
High risk 453 1.59 (1.19-2.12) .002
Patient/donor CMV status at
transplantation*
Other 378 1.00
Positive/positive 195 1.29 (1.03-1.63) .029
RR indicates relative risk; CI, confidence interval; CMV, cytomegalovirus.
*Missing data: N 5 27.The factors associated with a significantly better
OS by univariate analysis (P # .05) in the younger
and the older groups were, respectively, a lymphoid
disease (P5 .04) and a standard risk at transplantationFigure 1. (A) OS, DFS, and NRM after RIC allo-HSCT for the entire
study population (N 5 600). Abscissa: years; ordinate: % of survival.
(B) OS after RIC allo-HSCT: comparison between patients 60-65 years
old ( ___ ) (N 5 493) and patients .65 years old (- - -) (N 5 107).
Abscissa: years; ordinate: % of survival.
Biol Blood Marrow Transplant 18:289-294, 2012 293RIC Allo-HSCT in Elderly Patients(P 5 .008) for the former, and a donor CMV negative
status (P 5 .01) and a standard risk at transplantation
(P 5 .05) for the latter.
Median DFS was 14.6 (95% CI: 10.0-19.1)
months, and the probability of 2-year DFS was
41.8% (95% CI: 37.6-46.2%) (Figure 1A). At last
follow-up, 320 patients have died, with relapse being
the cause of death in 41% of cases (n5 132). Compar-
isons of both groups according to age ($65 vs .65
years) showed no difference in terms of engraftment,
OS, DFS, aGVHD and cGVHD, relapse rates, and
NRM (Table 1B and Figure 1B).
The multivariate analysis for survival is given in
Table 1C. This analysis showed that when adjusted
for disease risk and patient/donor CMV status, there
was no statistical difference in risk of mortality be-
tween patients age 60 to 65 and those .65 years old
(relative risk 5 1.08, 95% CI: 0.81-1.44, P 5 .62).DISCUSSION
Despite the limitations of this heterogeneous ret-
rospective registry analysis, over and above the lack
of comorbidity data and selection bias, especially in
older patients, results from the current analysis suggest
that RIC allo-HSCT is feasible beyond the age of 65.
We observed relatively acceptable outcomes compared
with the results of previously published series includ-
ing younger patients [1-7] or elderly patients with
acute myelogenous leukemia where the feasibility of
RIC allo-HSCT has been previously reported, with
NRM rates of 10% to 34%, DFS of 31% to 44%,
and OS of 33% to 52%, with follow-ups ranging
from 2 to 5 years [3,12,17-19,21]. Such results are of
importance as most hematologic diseases occur after
the age of 60.
The current data also suggests that disease status is
likely the most important prognostic factor for trans-
plant outcome (Table 1C), as highlighted in other
studies [14,18,20,21]. As a consequence, we would
recommend allografts for elderly patients in the
situation of CR1, especially in patients with no
indolent hematologic diseases, namely, myeloid
disorders. Also, in order to improve outcome, some
postallograft strategies as maintenance therapy
should be tested in the future.
Two recent series have specifically addressed the
results ofRIC-allo-HSCTafter the age of 65: 1 in acute
myelogenous leukemia (N5 55) [19] and 1 in patients
with various hematologic diseases (N5 48) [20]. Both
studies showed similar outcomes (NRM,DFS, andOS)
between patients age 60 to 65 and after age 65, further
suggesting that older age per se should not be a contra-
indication to performing allo-HSCT. Obviously, pa-
tients from the older age group were highly selected,
and were likely to have a good performance statuswith little or no comorbidities. Unfortunately, given
the registry nature of this study, comorbidities were
not captured. Unlike chronologic age, physiologic ag-
ing combined with a precise assessment of comorbid-
ities are likely the most important parameters to be
taken into account. Indeed, following the pioneering
work of Sorror and colleagues [8,9], it has become
increasingly important to optimize pretransplantation
risk assessment to improve allo-HSCT decision mak-
ing. Although single-organ comorbidity involving the
liver, lung, heart, or kidney has been traditionally found
to cause organ toxicity after allo-HSCT, more recent
efforts have results in the advent of weighted scoring
systems that could sensitively capture multiple-organ
comorbidities before allo-HSCT, such as the HSCT-
comorbidity index [22,23]. Nevertheless, further
understanding of biologic aging and enhancing the
applicability of comorbidities coding will
undoubtedly guide new prophylactic and therapeutic
interventions to lessen allo-HSCT NRM, especially
in older patients where common scoring systems
seem to be insufficient for predicting outcomes [24].
Only 3 patients were allografted after age 70 in this
large series from the SFGM-TC. It is likely that this
low incidence reflects what represents the threshold
by which hematologists assert themselves to perform
RIC allo-HSCT, as no series has been published so
far considering these very elderly patients. As men-
tioned before, most trials, at least in France, include
patients less than 65 years of age. In order to know if
RIC allo-HSCT is useful in this particular setting,
prospective studies should be proposed, using specific
comorbidity scoring systems taking into account age,
performans status, and comorbidities for eligibility,
as mentioned previously.
From the HLA-related donor perspective, per-
forming allo-HSCT in elderly patients raised the is-
sue of stem cell donation by elderly donors (up to
80 years in our cohort), which should be addressed
prospectively in terms of safety and graft quality
[25,26].
In conclusion, despite its retrospective nature and
the inherent selection biases, results from this large
analysis suggest that in selected patients, RIC allo-
HSCT may allow for similar outcomes in patients
between 60 and 65 years old and patients between 65
and 70 years old. The role of allo-HSCT remains still
unclear after age 70. Prospective studies incorporating
pretransplantation risk assessment scoring systems are
warranted in elderly patients who are potential
candidates for RIC allo-HSCT.ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
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